Congestive Heart Failure Chf Market

DelveInsight’s ‘Congestive Heart Failure (CHF) - Market Insights, Epidemiology and Market Forecast– 2030’ report delivers an in-depth understanding of the Congestive Heart Failure, historical and forecasted epidemiology as well as the Congestive Heart Failure market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Congestive Heart Failure (CHF) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Congestive Heart Failure (CHF) market size from 2018 to 2030. The report also covers current Congestive Heart Failure (CHF) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Congestive Heart Failure Disease Understanding and Treatment Algorithm

Congestive Heart Failure Overview

Heart Failure (HF) is also known as congestive HF. It is also bifurcated as left-side HF (when the heart is unable to pump enough oxygen in the blood to the body) and right-side HF (when the heart is unable to fill itself with enough blood). Another term for HF is cor pulmonale which means that right-side HF is caused by high blood pressure in the pulmonary arteries and right ventricle. Some people face the problem of HF when the heart has trouble pumping enough blood to support other organs in the body. Some people have a hardening and stiffening of the heart muscle themself, which blocks or reduces blood flow towards the heart. HF initially causes the shortness of breath and fatigue (tiredness) and the right-side may further cause fluid to build up in the feet, ankles, legs, liver, abdomen, and the veins in the neck.

 

The body depends on the heart to pump and deliver oxygen and nutrient-rich blood to every cell. When the cells are nourished accurately, the body gains the ability to work normally. With HF, the weakened heart is not able to supply nutrients to the cells with enough blood which results in fatigue and shortness of breath and some people coughing (American Heart Association, n.d.)

 

HF is triggered by structural and functional limitations in the myocardium resulting in damage of ventricular filling or the ejection of blood by the heart. The most common cause for HF is lowering of the left ventricular myocardial utility along with the dysfunction of pericardium, myocardium, endocardium, heart valves or large vessels alone or in the combination. Some of the major pathogenic mechanisms leading to HF are excessive neurohumoral stimulation, irregular myocyte calcium cycling, augmented hemodynamic overload, ischemic dysfunction, ventricular remodeling, extreme or inadequate production of the extracellular matrix, enhanced apoptosis and genetic mutations.

 

Congestive Heart Failure Diagnosis

The assessment for HF is achieved using numerous parameters, like physical testing of the patient to know the occurrence of clinical symptoms of the HF, various blood tests, which includes complete blood count, urine analysis, serum creatinine, glucose, lipid fasting profile, metabolic profiling for serum electrolytes which includes magnesium and calcium, blood urea nitrogen, liver tests, and thyroid hormone estimation.

 

The diagnosis is normally measured whether a patient has a disease or condition that can cause HF in different forms like elevated blood pressure, ischemic heart problem, or diabetes. There is no single diagnostic test for the determination of the HF. If a person has signs and symptoms of HF, then the physician recommends one or more tests which will be completed through cardiologist.

 

Congestive Heart Failure Treatment

The available treatment can be divided into different drugs classes like angiotensin-converting enzyme inhibitors, angiotensin receptor II blockers, beta-blockers, aldosterone antagonists, amiodarone antiaggregants, anticoagulants, calcium antagonists, diuretics, nitrates, and others. The approved therapies for HF include Entresto and Corlanor, in addition to Jardince, Farxiga, and Verquvo, which are recently approved treatments for HF patients.

 

Lifestyle modifications, such as cessation of smoking and alcohol consumption (especially if this is thought to be the etiology), weight loss (where appropriate) and engagement in aerobic exercise, should be encouraged. Immunization against influenza (yearly) and pneumococcus is recommended. Fluid intake should be restricted to between 1.5 and 2 L/day and the patient advised of the importance of monitoring fluid balance (e.g., daily weights). Salt-rich foods should be avoided.

Congestive Heart Failure Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Population of HF, Diagnosed Prevalent Population of HF, Gender-specific diagnosed prevalent cases of HF, Age-specific diagnosed prevalent cases of HF, NYHA class-specific diagnosed prevalent cases of HF, Type-specific diagnosed prevalent cases of HF, Diagnosed prevalent cases of HF with Ejection Fraction, Diagnosed Prevalent cases of HF associated with comorbidities scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2018 to 2030.

 

Key Findings

  • Total Diagnosed Prevalent Cases of Heart Failure (HF) in the 7MM was found to be 12,602,028 in 2020, which is expected to grow during the study period (2018-2030).
  • Among 7MM, the United States has the highest diagnosed prevalent population of HF, i.e., 5,163,119 cases in 2020, which is 40.97% of the total diagnosed cases of HF in the 7MM.
  • In EU-5, Germany has the highest number of diagnosed cases, i.e., 2,216,497 followed by Spain with 1,283,827 cases and Italy with 1,164,031 cases. While, UK has the least number of cases with 728,547 in 2020.
  • There are several Heart Failure related comorbidities which include obesity, hyperlipidemia, metabolic syndrome, and others. Amongst them in the US, in 2020, 3,837,746, 2,237,179, 991,319, 1,626,382, 1,587,659, 3,097,871, and 2,065,247 cases were observed in Hypertension, Diabetes Mellitus, Chronic Kidney Disease, Atrial Fibrillation, COPD, Ischemic heart disease, and Dilated cardiomyopathy.
  • Age-specific diagnosed prevalent cases are seen maximum in the age group of 75–84 (1,607,918) and lowest in <44 (155,410) in 2020, this is due to the progressive aging of the population as well as improved and better survival after cardiac insults, such as myocardial infarction, especially in developed countries.
  • In 2020, the estimated cases of HFpEF (HFmEF) and HFrEF in the US were 3,097,871 and 2,065,247 which is expected to increase by 2030.
  • In 2020, New York Heart Association (NYHA) Classification is comprised of class I (No symptoms and no limitation in ordinary physical activity), class II (Mild symptoms and slight limitation during ordinary activity), class III (Marked limitation in activity due to symptoms, even during less than ordinary activity), and class IV (Severe limitations) cases which were estimated to be 2,597,106, 1,492,063, 509,236, and 509,236 cases, in the US.
  • In 2020, the estimated cases of acute heart failure and chronic heart failure in US were 1,548,936 and 3,614,183, respectively.
  • Heart failure is an important cause of morbidity and mortality in women, and the patients tend to develop it at an older age. According to the analysis, in 2020, the estimated cases of HF were 2,478,297 in males and 2,684,822 in females, in the US.

Country Wise- Congestive Heart Failure Epidemiology

The epidemiology segment also provides the Congestive Heart Failure epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Congestive Heart Failure Drug Chapters

The drug chapter segment of the Congestive Heart Failure report encloses the detailed analysis of Congestive Heart Failure mid and late stage pipeline drugs. It also helps to understand the Congestive Heart Failure clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.

 

Congestive Heart Failure Marketed Drugs

 

Entresto (Sacubitril and Valsartan): Novartis

Entresto combines a neprilysin inhibitor and an angiotensin II receptor blocker which reduces NT-proBNP and is expected to improve cardiovascular outcomes. Sacubitril is a neprilysin inhibitor. Valsartan, on the other hand, is an angiotensin II receptor blocker, also known as ARB. The drug keeps blood vessels from contracting and helps in decreasing the blood pressure, and progresses blood flow. The recommended starting dose of Entresto is 49/51 mg (sacubitril/valsartan) twice daily. Double the dose of Entresto after 2–4 weeks to the target maintenance dose of 97/103 mg (sacubitril/valsartan) twice daily, as tolerated by the patient. In February 2021, Novartis announced that the US FDA had approved the following expanded indication for Entresto (sacubitril/valsartan): to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with CHF.

Products detail in the report…

 

Jardiance (Empagliflozin): Boehringer Ingelheim and Eli Lilly

Jardiance is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated to reduce the risk of cardiovascular death plus hospitalization for heart failure in adults with heart failure and reduce ejection fraction. Sodium-glucose cotransporter 2 (SGLT2) is the predominant transporter responsible for the reabsorption of glucose from the glomerular filtrate back into circulation. Empagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, empagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, thereby increasing urinary glucose excretion. In August 2021, Boehringer Ingelheim and Eli Lilly and Company announced that the US FDA had approved Jardiance (empagliflozin) 10 mg to reduce the risk of cardiovascular death plus hospitalization for heart failure in adults with HFrEF. In September 2021, Boehringer Ingelheim and Eli Lilly and Company announced the US FDA had granted Breakthrough Therapy designation for empagliflozin as an investigational treatment for adults with HFpEF.

Products detail in the report…

 

Verquvo (Vericiguat): Bayer and Merck

Verquvo is a soluble guanylate cyclase (sGC) stimulator, indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient intravenous diuretics in adults with symptomatic chronic HF and ejection fraction less than 45%. The recommended starting dose of Verquvo is 2.5 mg orally once daily with food. In January 2021, Bayer announced that the US FDA approved soluble guanylate cyclase (sGC) stimulator vericiguat under the brand name Verquvo.

Products detail in the report…

 

Farxiga (Dapagliflozin): AstraZeneca

Farxiga is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. The drug is also being studied in HFpEF (DELIVER Phase III trial) with data and estimated filing acceptance anticipated in the first half of 2022 in the US, EU and Japan, myocardial infarction (DAPA-MI) with estimated filing acceptance anticipated in 2022+ in the US and EU, heart failure with CKD. In May 2020, AstraZeneca’s Farxiga (dapagliflozin) was approved in the US to reduce the risk of cardiovascular (CV) death and hospitalization for heart failure in adults with heart failure (NYHA class II-IV) with reduced ejection fraction (HFrEF) with and without type 2 diabetes (T2D). In July 2020, AstraZeneca was granted Fast Track designation in the US for the development of Farxiga (dapagliflozin) to reduce the risk of hospitalization for heart failure (hHF) or cardiovascular (CV) death in adults following an acute myocardial infarction (MI) or heart attack.

Products detail in the report…

 

Corlanor (ivabradine): Amgen

Ivabradine comes under the brand name Corlanor, a new heart rate lowering medicine used as the symptomatic treatment in the case of stable angina pectoralis and chronic heart failure.  The drug helps lower heart rate by selectively inhibiting If channels in the heart through a concentration-dependent method but does not affect any other cardiac ionic channels. The drug also acts by entering and getting attached to a site on the channel pore at the intracellular side and disturbs If ion current movement. In May 2019, the US FDA approved the use of Corlanor to treat stable symptomatic HF due to dilated cardiomyopathy (DCM) in pediatric patients aged 6 months and older, who are in sinus rhythm with an elevated heart rate.

Products detail in the report…

 

Congestive Heart Failure Emerging Drugs

 

OPC-61815: Otsuka Pharmaceutical

OPC-61815 is a prodrug of oral tolvaptan (tolvaptan sodium phosphate), with improved water solubility, and is considered suitable for intravenous administration. Tolvaptan, discovered by Otsuka, is a novel compound that is an orally available antagonist of the vasopressin V2-receptor. The company has also submitted a New Drug Application (NDA) to the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan to seek manufacturing and marketing approval of OPC-61815 for the treatment of cardiac edema. If this drug candidate is approved for use as an intravenous diuretic, it will provide a new treatment option for patients with cardiac edema who cannot take tolvaptan orally. The company has completed two Phase III trials of the drug in CHF patients in Japan. In the clinical Phase III trial in Japan, the efficacy and safety of this compound were compared with 15 mg tolvaptan tablets in 294 patients with cardiac edema. Outcomes showed noninferiority of OPC-61815 vs. tolvaptan 15 mg tablet in the primary endpoint of change in body weight from baseline at the final dose.

Products detail in the report…

 

Omecamtiv Mecarbil: Cytokinetics

Omecamtiv mecarbil (AMG 423, CK-1827452) is a small molecule drug that is administered orally. It is currently in Phase III trial and was under development by Amgen in collaboration with Cytokinetics and Servier for the treatment of CHF. The drug works by increasing cardiac contractility by specifically activating the enzymatic domain of the cardiac myosin heavy chain. It also helps in generating the force of the motor protein in the cardiac sarcomere. In May 2020, the US FDA granted Fast Track designation for omecamtiv mecarbil, which is being developed for the potential treatment of HFrEF. The drug is currently in a second Phase III (METEORIC-HF) study to evaluate its potential to increase exercise performance in HFrEF, for which results are expected in 2H 2022. Furthermore, the company is expecting to submit a US NDA for omecamtiv mecarbil in 2H 2021.

Products detail in the report…

 

AZD4831: AstraZeneca

AZD4831 is an investigational, first-in-class myeloperoxidase (MPO) inhibitor for patients diagnosed with HFpEF to increase survival, reduce hospitalization and improve quality of life. The molecule was developed in-house at AstraZeneca. AZD4831 inhibits MPO, known to cause the formation of hypochlorous acid and other free radicals that interfere with microvascular function (the tiny artery blood vessels in the heart). AZD4831 is currently being investigated in Phase II/III trial (ENDEAVOR) in HFpEF.

Products detail in the report…

 

Furoscix (furosemide injection): scPharmaceuticals

Furoscix (furosemide injection) is an investigational, proprietary furosemide solution formulated to a neutral pH, designed to allow for subcutaneous infusion via a wearable, pre-programmed on-body infusor for outpatient self-administration. It is a novel formulation of furosemide contained in a pre-filled Crystal Zenith cartridge. The user inserts the pre-filled cartridge into the wearable device, secures it to the abdomen via a medical-grade adhesive, and a subcutaneous infusion of Furoscix is administered through a pre-programmed, biphasic delivery profile with 30 mg administered over the first hour, followed by 12.5 mg/h for the subsequent 4 h (a total dose of 80 mg (10 mL) over 5 h).

Products detail in the report…

 

Rexlemestrocel-L (Revascor): Mesoblast

Revascor is a Phase III product candidate being developed to treat advanced and end-stage chronic heart failure. Revascor consists of 150 million mesenchymal precursor cells (MPCs) administered by direct injection into the heart muscle in patients suffering from CHF and progressive loss of heart function. MPCs release a range of factors when triggered by specific receptor-ligand interactions within the damaged tissue. In June 2019, the US FDA granted rexlemestrocel-L an Orphan Drug Designation to prevent post-implantation mucosal bleeding in end-stage chronic heart failure patients who require a left ventricular assist device (LVAD). Mesoblast has completed a Phase III trial. Based on the observed reduction in mortality and morbidity in this Phase III trial, it intends to meet with the FDA to discuss a potential approval pathway.

Products detail in the report…

 

Finerenone (Kerendia): Bayer

Finerenone (Kerendia/BAY 94-8862) is an investigational novel, nonsteroidal, selective mineralocorticoid receptor antagonist (MRA) that has been shown to block many of the harmful effects of mineralocorticoid receptor (MR) overactivation, which is a major driver of kidney and heart damage. The drug is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease associated with type 2 diabetes (FDA, 2021). The anticipated patent expiration of Finerenone (Kerendia) is 2029. The drug is currently in a Phase III trial in patients with heart failure and left ventricular ejection fraction greater or equal to 40%.

Products detail in the report…

 

Semaglutide 2.4 mg: Novo Nordisk

Semaglutide 2.4 mg injection is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. The drug is currently in a phase III trial in patients living with heart failure and obesity (STEP HFpEF) and in another phase III trial in patients living with heart failure, obesity and type 2 diabetes (STEP HFpEF DM).

Products detail in the report…

 

Sotagliflozin: Lexicon Pharmaceuticals

Discovered using Lexicon’s unique approach to gene science, sotagliflozin is an oral dual inhibitor of two proteins responsible for glucose regulation known as sodium-glucose co-transporter types 1 and 2 (SGLT1 and SGLT2). SGLT1 is responsible for glucose absorption in the gastrointestinal tract, and SGLT2 is responsible for glucose reabsorption by the kidney. In November 2020, the company reported results from both the SOLOIST and SCORED outcome studies, which achieved their primary endpoints by demonstrating statistically significant reductions in total cardiovascular deaths, hospitalizations for heart failure, and urgent heart failure visits in patients treated with sotagliflozin as compared with placebo. However, the trials ended early because of the loss of funding from the sponsor. In August 2021, the new guidelines from the European Society of Cardiology recommended addition of SGLT inhibitors, including sotagliflozin, to standard of care for patients with acute CHF.

Products detail in the report…

Congestive Heart Failure Market Outlook

Currently, the treatment of heart failure is dependent on angiotensin-converting enzyme inhibitors, angiotensin receptor II blockers, beta-blockers, and diuretics. Additionally, other therapies, such as aldosterone antagonists, amiodarone, antiaggregants, anticoagulants, calcium antagonists, diuretics, nitrates, among others, are used for the treatment of patients affected by heart failure.

 

Angiotensin-converting enzyme (ACE) inhibitors are essential medicines for the management of heart failure. This helps in reducing blood pressure and in the relaxation of blood vessels. This further leads to better blood flow, and the heart is able to pump more blood to the rest of the body. Some examples of ACE inhibitors are captopril, enalapril, ramipril, quinapril, lisinopril, and others.

 

Angiotensin-receptor II blocker (ARB) works similarly to ACE inhibitors. It helps in the relaxation of veins and arteries to lower the blood pressure and ease the process of the heart to pump blood. Angiotensin is a chemical in the body that helps in contracting the blood vessels. Some examples of ARBs are olmesartan, azilsartan, eprosartan, and valsartan, among others (Mayo Clinic, n.d.).  

 

Beta-blockers are a class of drugs used to control heart failure symptoms that are made worse by some hormones called catecholamines. The body releases these hormones as a part of its response to heart failure. Beta-blockers are used because they can slow the progression of systolic forms of heart failure. Beta-blockers may also be used to treat left ventricular systolic dysfunction in people who are stable and have no symptoms or only mild to moderate heart failure symptoms. Some examples of beta-blockers are bisoprolol, carvedilol, and metoprolol, among others.

 

Diuretics are commonly prescribed as symptomatic relief for the treatment of patients affected by heart failure. The drugs get free of the excess fluids, which cause swollen legs, shortness of breath, weight gain, and coughing. Some examples of diuretics are chlorthalidone, ethacrynic acid (Edecrin), and furosemide (Lasix), among others.

 

Also, according to the recent press release by the European Society of Cardiology (ESC), patients with heart failure do not like diuretics because they sense that they will get cramps and have to stay at home to use the bathroom. The recent trial of ReBIC-1 results shows that patients with stable heart failure who stop diuretics do not have more dyspnea than those who were continuously taking the drug. Withdrawal also does not lead to improved reuse of diuretics; around 20% of patients in both groups needed a top-up, presumably for symptom relief during the trial. These findings also indicate that diuretics can be safely discontinued in heart failure patients meeting the trial’s eligibility criteria.

 

Entresto (sacubitril/valsartan) developed by Novartis is a first-in-class angiotensin receptor/neprilysin inhibitor approved and marketed for the treatment of chronic heart failure with reduced ejection fraction (HFrEF). The drug is designated to decrease cardiovascular death risk and related hospitalization for heart failure in patients with chronic heart failure (NYHA Class II–IV) and reduce ejection fraction. This drug got approval in the US in July 2015 for chronic heart failure associated with a reduced ejection fraction; in Europe, in November 2015 and in October 2019, it got approval for the pediatric patients with heart failure. Recently, in February 2021, Novartis announced that the US FDA had approved the following expanded indication for Entresto (sacubitril/valsartan) to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with CHF. As per the company press release, this is the first treatment with benefit for patients diagnosed with guideline-defined heart failure that includes those with heart failure with reduced ejection fraction (HFrEF) and many with heart failure with preserved ejection fraction (HFpEF).

 

Jardiance by Boehringer Ingelheim and Eli Lilly is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults genital or perineal area, along with fever or malaise, to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease and to reduce the risk of cardiovascular death plus hospitalization for heart failure in adults with heart failure and reduce ejection fraction. It is approved in US and EU for heart failure.

 

Key Findings

This section includes a glimpse of the Congestive Heart Failure 7MM market.

  • The market size of CHF in the 7MM is estimated to be USD 5,955 Million in 2020.
  • The current treatment market comprises of drug classes such as angiotensin-converting enzyme inhibitors, angiotensin receptor II blocker, beta-blockers, and diuretics, aldosterone antagonists, amiodarone, antiaggregants, anticoagulants, calcium antagonists, diuretics, nitrates, and others, along with approved therapies like Entresto, Corlanor, Jardince, Farxiga, and Verquvo.
  • Potential therapies expected to launch are as follows: OPC-61815 (Otsuka Pharmaceuticals), sotagliflozin (Lexicon Pharmaceuticals), omecamtiv mecarbil (Cytokinetics), AZD4831 (AstraZeneca), Furoscix infusor (scPharmaceuticals), Revascor (Rexlemestrocel-L) (Mesoblast), CardiAMP cell therapy (BioCardia), tirzepatide (Eli Lilly), semaglutide (Novo Nordisk), cimlanod (Bristol-Myers Squibb), lenrispodun (Intra-Cellular Therapies), levosimendan (Tenax Therapeutics), and others. The launch of these therapies may increase market size in the coming years, assisted by an increase in the Heart Failure patient pool.
  • The United States accounted for the largest market size of Congestive Heart Failure USD 4,042 Million in 2020, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
  • Among the EU5 countries, Germany had the largest market size with USD 577 million while the UK had the smallest with USD 187 million in 2020, which is expected to rise during the forecast period 2021–2030.
  • Japan accounts for USD 230 Million in 2020, which is expected to rise during the forecast period 2021–2030.

 

The United States Market Outlook

This section provides the total Congestive Heart Failure market size and market size by therapies in the United States.

 

EU-5 Market Outlook

The total Congestive Heart Failure market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

 

Japan Market Outlook

The total Congestive Heart Failure market size and market size by therapies in Japan are provided.

Congestive Heart Failure Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Congestive Heart Failure market or expected to get launched in the market during the study period 2018–2030. The analysis covers Congestive Heart Failure market uptake by drugs; patient uptake by therapies; and sales of each drug.

 

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Congestive Heart Failure Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for Congestive Heart Failure emerging therapies.

Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the Congestive Heart Failure market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Congestive Heart Failure, explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
  • Comprehensive insight has been provided into the Congestive Heart Failure epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Congestive Heart Failure are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of Congestive Heart Failure market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Congestive Heart Failure market.

Report Highlights

  • In the coming years, Congestive Heart Failure market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Congestive Heart Failure R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Delvelnsight has analysed the total prevalent and total diagnosed prevalent population of congestive heart failure.
  • Delvelnsight has analysed type-specific distribution of congestive heart failure. As per the analysis, chronic heart failure is more prevalent than acute heart failure.
  • DelveInsight estimates that there are several upcoming therapies targeting specific Congestive Heart Failure patient pool, which are catering to the needs of these earlier non-targeted patients are going to grab the market during the coming years.

Analyst Comments

  • The approval of three new candidates since 2020 has recently crowded the heart failure market where only two drugs were approved earlier.
  • The approval of Entresto to include patients with HFpEF will definitely provide an upper hand to the drug in the current market where Boehringer Ingelheim and Eli Lilly, and AstraZeneca are still struggling to find approval in the same patient population. But, as per the recently published results, Jardiance might overthrow Entresto from the market as the study found a 21% reduction in the risk of cardiovascular death or hospitalization for heart failure, the composite primary outcome, with Jardiance plus standard of care versus standard of care alone as compared to 13% benefit seen with Novartis’s Entresto in its HFpEF study. Based on these results, in September 2021, Boehringer Ingelheim and Eli Lilly and Company announced the US FDA had granted Breakthrough Therapy designation for empagliflozin as an investigational treatment for adults with HFpEF. Based on Phase III EMPEROR-Preserved trial.
  • The expanded approval of Jardiance is anticipated to rule over Entresto and Farxiga in the HFpEF segment.

Congestive Heart Failure Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Congestive Heart Failure Pipeline Analysis
  • Congestive Heart Failure Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Congestive Heart Failure Report Key Strengths

  • Ten Years Forecast
  • 7MM Coverage
  • Congestive Heart Failure Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Congestive Heart Failure Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Congestive Heart Failure market share (%) distribution in 2018 and how it would look like in 2030?
  • What would be the Congestive Heart Failure total market size as well as market size by therapies across the 7MM during the forecast period (2021–2030)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest Congestive Heart Failure market size during the forecast period (2021–2030)?
  • At what CAGR, the Congestive Heart Failure market is expected to grow at the 7MM level during the forecast period (2021–2030)?
  • What would be the Congestive Heart Failure market outlook across the 7MM during the forecast period (2021–2030)?
  • What would be the Congestive Heart Failure market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

 

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of Congestive Heart Failure?
  • What is the historical Congestive Heart Failure patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of Congestive Heart Failure at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Congestive Heart Failure?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of Congestive Heart Failure during the forecast period (2021–2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2021–2030)?


Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the treatment of Congestive Heart Failure along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Congestive Heart Failure in the US and Europe?
  • What are the Congestive Heart Failure marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Congestive Heart Failure?
  • How many therapies are developed by each company for the treatment of Congestive Heart Failure?
  • How many emerging therapies are in the mid-stage and late stage of development for the treatment of Congestive Heart Failure?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Congestive Heart Failure therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Congestive Heart Failure and their status?
  • What are the key designations that have been granted for the emerging therapies for Congestive Heart Failure?
  • What are the 7MM historical and forecasted market of Congestive Heart Failure?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Congestive Heart Failure.
  • To understand the future market competition in the Congestive Heart Failure market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Congestive HF in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for Congestive Heart Failure market.
  • To understand the future market competition in the Congestive Heart Failure market.

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

5. SWOT Analysis

6. Congestive Heart Failure (CHF) Market Overview at a Glance

6.1. Market Share (%) Distribution of CHF by therapies in 2021

6.2. Market Share (%) Distribution of CHF by therapies in 2030

7. Disease Background and Overview

7.1. Introduction

7.2. Causes of HF

7.3. Signs and Symptoms

7.4. Stages of HF

7.4.1. Stage A

7.4.2. Stage B

7.4.3. Stage C

7.4.4. Stage D and reduced E

7.5. Classification of HF

7.6. Common pathophysiologic mechanisms in HF

7.6.1. Structural Heart Disease and Mechanical Stress: Pressure/Volume Overload

7.6.2. Neurohormonal Dysregulation

7.6.3. Ischemic Injury: Replacement Fibrosis and Hibernating Myocardium

7.6.4. Abnormal Intracellular Calcium Handling

7.6.5. Genetic Mutations

7.6.6. Biomarkers for the HF

7.7. Diagnosis

7.7.1. Medical and Family Histories

7.8. Diagnostic Tests

7.8.1. EKG (Electrocardiogram)

7.8.2. Chest x-ray

7.8.3. Echocardiography

7.8.4. Doppler Ultrasound

7.8.5. Holter Monitor

7.8.6. Nuclear Heart Scan

7.8.7. Cardiac Catheterization

7.8.8. Coronary Angiography

7.8.9. Stress Test

7.8.10.  Cardiac MRI

7.9. Differential Diagnosis

8. Treatment

8.1. Angiotensin-converting enzyme (ACE) inhibitors

8.2. Angiotensin II receptor blockers (ARBs)

8.3. Mineralocorticoid receptor antagonists (MRAs)

8.4. If-Channel Inhibitor

8.5. Beta-blockers

8.6. Angiotensin-Receptor Neprilysin Inhibitors (ARNIs)

8.7. Diuretics

8.8. Digoxin (Lanoxin)

8.9. Hydralazine and isosorbide dinitrate

8.10. Statins

8.11. Anticoagulants

8.12. Dual Antiplatelet Therapy (DAPT)

8.13. Unique characteristics of heart failure treatment in Japan

8.13.1. Carperitide

8.13.2. Nicorandil

8.13.3. Landiolol

8.13.4. Tolvaptan

8.13.5. Pimobendan

8.13.6. Waon therapy

8.14. Non-pharmacological intervention and lifestyle modification

9. Heart Failure with Preserved Ejection Fraction: Diagnosis and Management (2017)

9.1. Key Recommendations for Practice

9.2. Recommendations on Treatment

10. ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic HF (2021)

10.1. Guidelines for Diagnosis

10.2. Guidelines for Patients with Heart Failure With Reduced Ejection Fraction (HRrEF)

10.3. Guidelines for Cardiac Rhythm Management for Heart Failure with Reduced Ejection Fraction

10.3.1. Guidelines for cardiac resynchronization therapy

10.4. Guidelines for Patients with Heart Failure With Mildly Reduced Ejection Fraction (HRmrEF)

10.5. Guidelines for Patients with Heart Failure With Preserved Ejection Fraction (HRpEF)

10.6. Guidelines for Multidisciplinary Team Management for the Prevention and Treatment of Chronic Heart Failure

10.6.1. Guidelines for Exercise Rehabilitation

10.7. Guidelines for Advanced Heart Failure

10.8. Guidelines for acute heart failure

10.8.1. Guidelines for Short-term Mechanical Circulatory Support

10.8.2. Guidelines for Predischarge Assessment and Post-discharge Management Planning

10.9. Guidelines on Cardiovascular Comorbidities

10.9.1. Atrial fibrillation

10.9.2. Chronic Coronary Syndromes

10.9.3. Valvular Heart Disease

10.9.4. Hypertension

11. JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure (Update From 2017)

11.1. Guidelines on Pharmacologic Therapy

11.2. Guidelines on If Channel Blocker or HCN Channel Blocker; Ivabradine

11.3. Guidelines on ARNI: Sacubitril/valsartan

11.4. Guidelines on SGLT2 Inhibitors

11.5. Guidelines on Nonpharmacologic Therapy

11.5.1. Percutaneous Mitral Valve Repair System (MitraClip)

11.5.2. Transcatheter Aortic Valve Implantation (TAVI)

11.6. Guidelines on Surgical Treatment

11.6.1. Mechanical Circulatory Support

11.6.2. Catheter-Based Transaortic Microaxial Pumps (Impella)

11.7. Guidelines for disease management

12. American College of Cardiology (ACC), American Heart Association (AHA), and HF Society of America (HFSA) (2021)

13. Chronic Heart Failure in Adults: Diagnosis and Management (NICE Guidelines 2018)

13.1. Guidelines on Diagnosing Heart Failure

13.1.1. Symptoms, Signs, and Investigations

13.1.2. Heart Failure Caused by Valve Disease

13.1.3. Reviewing Existing Diagnoses

13.2. Guidelines on Treating Heart Failure with Reduced Ejection Fraction

13.2.1. First-line Treatment

13.2.2. ACE Inhibitors

13.2.3. Alternative Treatments if ACE Inhibitors are Not Tolerated

13.2.4. Beta-blockers

13.2.5. Mineralocorticoid Receptor Antagonists

13.3. Guidelines on Specialist Treatment

13.3.1. Ivabradine

13.3.2. Sacubitril Valsartan

13.3.3. Hydralazine in Combination with Nitrate

13.3.4. Digoxin

13.4. Guidelines on treating HF with reduced ejection fraction in people with chronic kidney disease

13.5. Guidelines on managing all Types of Heart Failure

13.5.1. Pharmacological Treatment

13.5.2. Vaccinations

13.5.3. Contraception and Pregnancy

13.6. Guidelines on interventional procedures

13.6.1. Coronary Revascularization

13.6.2. Cardiac Transplantation

13.6.3. Implantable Cardioverter-defibrillators and Cardiac Resynchronization Therapy

14. Acute heart failure: Diagnosis And Management (NICE Guidelines 2014)

14.1. Guidelines on Diagnosis, Assessment, and Monitoring

14.2. Guidelines on Initial Pharmacological Treatment

14.3. Guidelines on Initial Nonpharmacological Treatment

14.4. Guidelines for Treatment after Stabilization

14.5. Guidelines on Valvular Surgery and Percutaneous Intervention

14.6. Guidelines on Mechanical Assist Devices

15. Epidemiology and Patient Population

15.1. Key Findings

15.2. Total Diagnosed Prevalent Patient Population of Heart Failure in the 7MM

16. Country Wise-Epidemiology of HF

16.1. The United States

16.1.1. Assumptions and Rationale

16.1.2. Prevalent Population of Heart Failure in the United States

16.1.3. Diagnosed Prevalent Population of Heart Failure in the United States

16.1.4. Gender-specific diagnosed prevalent cases of Heart Failure in the United States

16.1.5. Age-specific diagnosed prevalent cases of Heart Failure in the United States

16.1.6. NYHA class-specific diagnosed prevalent cases in the United States

16.1.7. Diagnosed prevalent cases of Heart Failure with Ejection Fraction in the United States

16.1.8. Diagnosed Prevalent cases of Heart Failure associated with comorbidities in the United States

16.2. EU5

16.2.1. Germany

16.2.2. France

16.2.3. Italy

16.2.4. Spain

16.2.5. United Kingdom

16.3. Japan

16.3.1. Assumptions and Rationale

16.3.2. Prevalent Population of Heart Failure in Japan

16.3.3. Diagnosed Prevalent Population of Heart Failure in Japan

16.3.4. Gender-specific diagnosed prevalent cases of Heart Failure in Japan

16.3.5. Age-specific diagnosed prevalent cases of Heart Failure in Japan

16.3.6. NYHA class-specific diagnosed prevalent cases in Japan

16.3.7. Diagnosed prevalent cases of Heart Failure with Ejection Fraction in Japan

16.3.8. Diagnosed Prevalent cases of Heart Failure associated with comorbidities in Japan

17. Organizations contributing towards CHF

18. Patient Journey

19. Marketed Drugs

19.1. Key Competitors

19.2. Entresto (Sacubitril and Valsartan): Novartis

19.2.1. Drug Description

19.2.2. Regulatory Milestones

19.2.3. Other Developmental Activities

19.2.4. Clinical Development Pipeline

19.2.5. Safety and Efficacy

19.2.6. Product Profile

19.3. Jardiance (Empagliflozin): Boehringer Ingelheim and Eli Lilly

19.3.1. Drug Description

19.3.2. Regulatory Milestones

19.3.3. Other Development Activities

19.3.4. Clinical Development Pipeline

19.3.5. Safety and Efficacy

19.3.6. Product Profile

19.4. Verquvo (Vericiguat): Bayer and Merck

19.4.1. Drug Description

19.4.2. Regulatory Milestones

19.4.3. Other Development Activities

19.4.4. Clinical Development Pipeline

19.4.5. Safety and Efficacy

19.4.6. Product Profile

19.5. Farxiga (Dapagliflozin): AstraZeneca

19.5.1. Drug Description

19.5.2. Regulatory Milestones

19.5.3. Other Development Activities

19.5.4. Clinical Development Pipeline

19.5.5. Safety and Efficacy

19.5.6. Product Profile

19.6. Corlanor (ivabradine): Amgen

19.6.1. Drug Description

19.6.2. Safety and Efficacy

19.6.3. Product Profile

20. Emerging Drugs

20.1.  Key Competitors

20.2. OPC-61815: Otsuka Pharmaceutical

20.2.1. Product Description

20.2.2. Clinical Development

20.2.3. Safety and Efficacy

20.3. Omecamtiv Mecarbil: Cytokinetics

20.3.1. Product Description

20.3.2. Clinical Development

20.3.3. Safety and Efficacy

20.4. AZD4831: AstraZeneca

20.4.1. Product Description

20.4.2. Clinical Development

20.4.3. Safety and Efficacy

20.5.      Rexlemestrocel-L (Revascor): Mesoblast

20.5.1.  Product Description

20.5.2.  Clinical Development

20.5.3.  Safety and Efficacy

20.6. Finerenone (Kerendia): Bayer

20.6.1. Product Description

20.6.2. Clinical Development

20.6.3. Safety and Efficacy

20.7. Semaglutide 2.4 mg: Novo Nordisk

20.7.1. Product Description

20.8. Furoscix (furosemide injection): scPharmaceuticals

20.8.1. Product Description

20.8.2. Clinical Development

20.8.3. Safety and Efficacy

20.9.      HNO (Nitroxyl) Donor (BMS-986231): Bristol-Myers Squibb

20.9.1. Product Description

20.9.2. Clinical Development

20.9.3. Safety and Efficacy

20.10. Lenrispodun (ITI - 214): Intra-Cellular Therapies

20.10.1. Product Description

20.10.2. Clinical Development

20.10.3. Safety and Efficacy

20.11. Levosimendan: Tenax Therapeutics

20.11.1. Product Description

20.11.2. Clinical Development

20.11.3. Safety and Efficacy

20.12. CardiAMPCell Therapy: BioCardia

20.12.1. Product Description

20.12.2. Clinical Development

20.12.3. Safety and Efficacy

20.13. Tirzepatide: Eli Lilly and Company

20.13.1. Product Description

20.13.2. Clinical Development

20.13.3. Safety and Efficacy

21. Potential of Current Therapies and Emerging Therapies

22. Congestive Heart Failure (CHF): Seven Major Market Analysis

22.1. Key Findings

22.2. Market Methodology

22.3. Market Size of Heart Failure by Current Therapies in the 7MM

22.4. Market Size of Heart Failure by Emerging Therapies in the 7MM

22.5. Market Outlook

22.6. Attribute Analysis

22.7. Key Market Forecast Assumptions

22.8. United States Market Size

22.8.1. Total Market Size of Heart Failure in the United States

22.8.2. Market Size of Heart Failure by Current Therapies in the United States

22.8.3. Market Size of Heart Failure by Emerging Therapies in the United States

22.9. EU-5 Market Size

22.9.1. Total Market size of Heart Failure in Europe

22.9.2. Market Size of Heart Failure by Current Therapies in Europe

22.9.3. Market Size of Heart Failure by Emerging Therapies in Europe

22.10. Japan

22.10.1. Total Market size of Heart Failure in Japan

22.10.2. Market Size of Heart Failure by Therapies in Japan

22.10.3. Market Size of Heart Failure by Therapies in Japan

23. Market Drivers

24. Market Barriers

25. Unmet Needs

26. Market Access and Reimbursement

27. Appendix

27.1. Bibliography

27.2. Report Methodology

28. DelveInsight Capabilities

29. Disclaimer

30. About DelveInsight

List of Table

Table 1: Summary of Congestive Heart Failure, Market, Epidemiology, and Key Events (2018–2030)

Table 2: Key Events

Table 3: HF Classification based on the New York Heart Association

Table 4: HF Classification based on the New York Heart Association

Table 5: HF Classification based on the American College of Cardiology

Table 6: Shift along the Frank-Starling Curve and Its Causes

Table 7: Characteristics of Other Biomarkers for HF

Table 8: Different test for the estimation of the HF

Table 9: Recommendation for Non-pharmacological intervention and lifestyle modification

Table 10: Key Recommendations

Table 11: ACC/AHA Recommendations by Stage of Heart Failure

Table 12: Recommendations and Levels of Evidence for Medications for HFrEF

Table 13: Recommendations for Measuring Biomarkers in HF

Table 14: Recommendations for managing blood pressure in HF

Table 15: Total Prevalent Patient Population of Heart Failure in the 7MM (2018–2030)

Table 16: Total Diagnosed Prevalent Patient Population of Heart Failure in the 7MM (2018–2030)

Table 17: Prevalent Population of Heart Failure in the United States (2018–2030)

Table 18: Diagnosed Prevalent Population of Heart Failure in the United States (2018–2030)

Table 19: Gender-specific diagnosed prevalent cases of Heart Failure in the United States (2018–2030)

Table 20: Age-specific diagnosed prevalent cases of Heart Failure in the United States (2018–2030)

Table 21: NYHA class-specific diagnosed prevalent cases in the United States (2018–2030)

Table 22: Diagnosed prevalent cases of Heart Failure with Ejection Fraction in the US (2018–2030)

Table 23: Diagnosed Prevalent cases of HF associated with comorbidities in the US (2018–2030)

Table 24: Prevalent Population of Heart Failure in Germany (2018–2030)

Table 25: Diagnosed Prevalent Population of Heart Failure in Germany (2018–2030)

Table 26: Gender-specific diagnosed prevalent cases of Heart Failure in Germany (2018–2030)

Table 27: Age-specific diagnosed prevalent cases of Heart Failure in Germany (2018–2030)

Table 28: NYHA class-specific diagnosed prevalent cases in Germany (2018–2030)

Table 29: Diagnosed prevalent cases of Heart Failure with Ejection Fraction in Germany (2018–2030)

Table 30: Diagnosed Prevalent cases of HF associated with comorbidities in Germany (2018–2030)

Table 31: Prevalent Population of Heart Failure in France (2018–2030)

Table 32: Diagnosed Prevalent Population of Heart Failure in France (2018–2030)

Table 33: Gender-specific diagnosed prevalent cases of Heart Failure in France (2018–2030)

Table 34: Age-specific diagnosed prevalent cases of Heart Failure in France (2018–2030)

Table 35: NYHA class-specific diagnosed prevalent cases in France (2018–2030)

Table 36: Diagnosed prevalent cases of Heart Failure with Ejection Fraction in France (2018–2030)

Table 37: Diagnosed Prevalent cases of HF associated with comorbidities in France (2018–2030)

Table 38: Prevalent Population of Heart Failure in Italy (2018–2030)

Table 39: Diagnosed Prevalent Population of Heart Failure in Italy (2018–2030)

Table 40: Gender-specific diagnosed prevalent cases of Heart Failure in Italy (2018–2030)

Table 41: Age-specific diagnosed prevalent cases of Heart Failure in Italy (2018–2030)

Table 42: NYHA class-specific diagnosed prevalent cases in Italy (2018–2030)

Table 43: Diagnosed prevalent cases of Heart Failure with Ejection Fraction in Italy (2018–2030)

Table 44: Diagnosed Prevalent cases of HF associated with comorbidities in Italy (2018–2030)

Table 45: Prevalent Population of Heart Failure in Spain (2018–2030)

Table 46: Diagnosed Prevalent Population of Heart Failure in Spain (2018–2030)

Table 47: Gender-specific diagnosed prevalent cases of Heart Failure in Spain (2018–2030)

Table 48: Age-specific diagnosed prevalent cases of Heart Failure in Spain (2018–2030)

Table 49: NYHA class-specific diagnosed prevalent cases in Spain (2018–2030)

Table 50: Diagnosed prevalent cases of Heart Failure with Ejection Fraction in Spain (2018–2030)

Table 51: Diagnosed Prevalent cases of HF associated with comorbidities in Spain (2018–2030)

Table 52: Prevalent Population of Heart Failure in the United Kingdom (2018–2030)

Table 53: Diagnosed Prevalent Population of Heart Failure in the United Kingdom (2018–2030)

Table 54: Gender-specific diagnosed prevalent cases of HF in the United Kingdom (2018–2030)

Table 55: Age-specific diagnosed prevalent cases of Heart Failure in the United Kingdom (2018–2030)

Table 56: NYHA class-specific diagnosed prevalent cases in the United Kingdom (2018–2030)

Table 57: Diagnosed prevalent cases of HF with Ejection Fraction in the United Kingdom (2018–2030)

Table 58: Diagnosed Prevalent cases of HF associated with comorbidities in the UK (2018–2030)

Table 59: Prevalent Population of Heart Failure in Japan (2018–2030)

Table 60: Diagnosed Prevalent Population of Heart Failure in Japan (2018–2030)

Table 61: Gender-specific diagnosed prevalent cases of Heart Failure in Japan (2018–2030)

Table 62: Age-specific diagnosed prevalent cases of Heart Failure in Japan (2018–2030)

Table 63: NYHA class-specific diagnosed prevalent cases in Japan (2018–2030)

Table 64: Diagnosed prevalent cases of Heart Failure with Ejection Fraction in Japan (2018–2030)

Table 65: Diagnosed Prevalent cases of HF associated with comorbidities in Japan (2018–2030)

Table 66: Organizations Contributing Toward the Fight Against Congestive Heart Failure (CHF)

Table 67: Comparison of Marketed drugs

Table 68: Entresto (sacubitril and valsartan), Clinical Trial Description, 2021

Table 69: Jardiance (Empagliflozin), Clinical Trial Description, 2021

Table 70: Verquvo (Vericiguat), Clinical Trial Description, 2021

Table 71: Farxiga (Dapagliflozin), Clinical Trial Description, 2021

Table 72: Comparison of Emerging drugs

Table 73: Comparison of Others Emerging drugs

Table 74: OPC-61815, Clinical Trial Description, 2021

Table 75: Omecamtiv mecarbil, Clinical Trial Description, 2021

Table 76: AZD4831, Clinical Trial Description, 2021

Table 77: Rexlemestrocel-L, Clinical Trial Description, 2021

Table 78: AT-001, Clinical Trial Description, 2021

Table 79: Semaglutide, Clinical Trial Description, 2021

Table 80: Sotagliflozin, Clinical Trial Description, 2021

Table 81: Furoscix Infusor, Clinical Trial Description, 2021

Table 82: BMS-986231, Clinical Trial Description, 2021

Table 83: Lenrispodun (ITI - 214), Clinical Trial Description, 2021

Table 84: Levosimendan, Clinical Trial Description, 2021

Table 85: CardiAMP Cell Therapy, Clinical Trial Description, 2021

Table 86: Tirzepatide, Clinical Trial Description, 2021

Table 87: Market Size of Heart Failure by Current therapies in the 7MM, in USD Million (2018–2030)

Table 88: Market Size of Heart Failure by Emerging therapies in the 7MM, in USD Million (2018–2030)

Table 89: Attribute analysis of Current and Emerging drugs

Table 90: Key Market Forecast Assumptions for OPC-61815

Table 91: Key Market Forecast Assumptions for Omecamtiv mecarbil

Table 92: Key Market Forecast Assumptions for AZD4831

Table 93: Key Market Forecast Assumptions for Rexlemestrocel-L (Revascor)

Table 94: Key Market Forecast Assumptions for Finerenone (Kerendia)

Table 95: Key Market Forecast Assumptions for Semaglutide

Table 96: Key Market Forecast Assumptions for BMS-986231

Table 97: Key Market Forecast Assumptions for Lenrispodun (ITI-214)

Table 98: Key Market Forecast Assumptions for Levosimendan

Table 99: Key Market Forecast Assumptions for CardiAMPCell Therapy

Table 100: Key Market Forecast Assumptions for Tirzepatide

Table 101: Key Market Forecast Assumptions for Furoscix Infusor

Table 102: Market Size of Heart Failure in the US, USD Million (2018–2030)

Table 103: Market Size of Heart Failure by Current therapies in the US, in USD Million (2018–2030)

Table 104: Market Size of Heart Failure by Emerging therapies in the US, USD Million (2018–2030)

Table 105: EU5 Market Size of Heart Failure in USD Million (2018–2030)

Table 106: EU5 Market Size of Heart Failure by Current Therapies in USD Million (2018–2030)

Table 107: EU5 Market Size of Heart Failure by Emerging Therapies in USD Million (2018–2030)

Table 108: Japan Market Size of Heart Failure in Japan, USD Million (2018–2030)

Table 109: Market Size of Heart Failure by Current therapies in Japan, in USD Million (2018–2030)

Table 110: Market Size of Heart Failure by Emerging therapies in Japan, USD Million (2018–2030)

List of Figures

Figure 1: Different Condition in HF

Figure 2: Stages of HF

Figure 3: Symptoms of HF

Figure 4: Different Classes of Drug

Figure 5: Total Prevalent Patient Population of Heart Failure in the 7MM (2018–2030)

Figure 6: Total Diagnosed Prevalent Patient Population of HF in the 7MM (2018-2030)

Figure 7: Prevalent Population of Heart Failure in the United States (2018–2030)

Figure 8: Diagnosed Prevalent Population of Heart Failure in the United States (2018–2030)

Figure 9: Gender-specific diagnosed prevalent cases of HF in the United States (2018–2030)

Figure 10: Age-specific diagnosed prevalent cases of Heart Failure in the United States (2018–2030)

Figure 11: NYHA class-specific diagnosed prevalent cases in the United States (2018–2030)

Figure 12: Diagnosed prevalent cases of Heart Failure with Ejection Fraction in the US (2018–2030)

Figure 13: Diagnosed Prevalent cases of HF associated with comorbidities in the US (2018–2030)

Figure 14: Prevalent Population of Heart Failure in Germany (2018–2030)

Figure 15: Diagnosed Prevalent Population of Heart Failure in Germany (2018–2030)

Figure 16: Gender-specific diagnosed prevalent cases of Heart Failure in Germany (2018–2030)

Figure 17: Age-specific diagnosed prevalent cases of Heart Failure in Germany (2018–2030)

Figure 18: NYHA class-specific diagnosed prevalent cases in Germany (2018–2030)

Figure 19: Diagnosed prevalent cases of Heart Failure with Ejection Fraction in Germany (2018–2030)

Figure 20: Diagnosed Prevalent cases of HF associated with comorbidities in Germany (2018–2030)

Figure 21: Prevalent Population of Heart Failure in France (2018–2030)

Figure 22: Diagnosed Prevalent Population of Heart Failure in France (2018–2030)

Figure 23: Gender-specific diagnosed prevalent cases of Heart Failure in France (2018–2030)

Figure 24: Age-specific diagnosed prevalent cases of Heart Failure in France (2018–2030)

Figure 25: NYHA class-specific diagnosed prevalent cases in France (2018–2030)

Figure 26: Diagnosed prevalent cases of Heart Failure with Ejection Fraction in France (2018–2030)

Figure 27: Diagnosed Prevalent cases of HF associated with comorbidities in France (2018–2030)

Figure 28: Prevalent Population of Heart Failure in Italy (2018–2030)

Figure 29: Diagnosed Prevalent Population of Heart Failure in Italy (2018–2030)

Figure 30: Gender-specific diagnosed prevalent cases of Heart Failure in Italy (2018–2030)

Figure 31: Age-specific diagnosed prevalent cases of Heart Failure in Italy (2018–2030)

Figure 32: NYHA class-specific diagnosed prevalent cases in Italy (2018–2030)

Figure 33: Diagnosed prevalent cases of Heart Failure with Ejection Fraction in Italy (2018–2030)

Figure 34: Diagnosed Prevalent cases of HF associated with comorbidities in Italy (2018–2030)

Figure 35: Prevalent Population of Heart Failure in Spain (2018–2030)

Figure 36: Diagnosed Prevalent Population of Heart Failure in Spain (2018–2030)

Figure 37: Gender-specific diagnosed prevalent cases of Heart Failure in Spain (2018–2030)

Figure 38: Age-specific diagnosed prevalent cases of Heart Failure in Spain (2018–2030)

Figure 39: NYHA class-specific diagnosed prevalent cases in Spain (2018–2030)

Figure 40: Diagnosed prevalent cases of Heart Failure with Ejection Fraction in Spain (2018–2030)

Figure 41: Diagnosed Prevalent cases of HF associated with comorbidities in Spain (2018–2030)

Figure 42: Prevalent Population of Heart Failure in the United Kingdom (2018–2030)

Figure 43: Diagnosed Prevalent Population of Heart Failure in the United Kingdom (2018–2030)

Figure 44: Gender-specific diagnosed prevalent cases of HF in the United Kingdom (2018–2030)

Figure 45: Age-specific diagnosed prevalent cases of Heart Failure in the United Kingdom (2018–2030)

Figure 46: NYHA class-specific diagnosed prevalent cases in the United Kingdom (2018–2030)

Figure 47: Diagnosed prevalent cases of HF with Ejection Fraction in the United Kingdom (2018–2030)

Figure 48: Diagnosed Prevalent cases of HF associated with comorbidities in the UK (2018–2030)

Figure 49: Prevalent Population of Heart Failure in Japan (2018–2030)

Figure 50: Diagnosed Prevalent Population of Heart Failure in Japan (2018–2030)

Figure 51: Gender-specific diagnosed prevalent cases of Heart Failure in Japan (2018–2030)

Figure 52: Age-specific diagnosed prevalent cases of Heart Failure in Japan (2018–2030)

Figure 53: NYHA class-specific diagnosed prevalent cases in Japan (2018–2030)

Figure 54: Diagnosed prevalent cases of Heart Failure with Ejection Fraction in Japan (2018–2030)

Figure 55: Diagnosed Prevalent cases of HF associated with comorbidities in Japan (2018–2030)

Figure 56: Market Size of HF by Current Therapies in the 7MM, in USD Million (2018–2030)

Figure 57: Market Size of HF by Emerging Therapies in the 7MM, in USD Million (2018–2030)

Figure 58: Market Size of Heart Failure in the US, USD Millions (2018–2030)

Figure 59: Market Size of Heart Failure by Current therapies in the US, USD Million (2018–2030)

Figure 60: Market Size of Heart Failure by Emerging therapies in the US, USD Million (2018–2030)

Figure 61: Market Size of Heart Failure in EU5, USD Million (2018–2030)

Figure 62: EU5 Market Size of Heart Failure by Current Therapies in USD Million (2018–2030)

Figure 63: EU5 Market Size of Heart Failure by Emerging Therapies in USD Million (2018–2030)

Figure 64: Market Size of Heart Failure in Japan, USD Million (2018–2030)

Figure 65: Japan Market Size of Heart Failure by Current Therapies, USD Million (2018–2030)

Figure 66: Japan Market Size of Heart Failure by Emerging Therapies, USD Million (2018–2030)

Novartis

Boehringer Ingelheim

Eli Lilly

Bayer

Merck

AstraZeneca

Amgen

Otsuka Pharmaceutical

Cytokinetics

Mesoblast

Novo Nordisk

scPharmaceuticals

Bristol-Myers Squibb

Intra-Cellular Therapies

Tenax Therapeutics

BioCardia

Forward to Friend

Need A Quote